In the JET-HCC study, it was reported that the frequency and severity of tivantinib-mediated hematotoxicity were similar between CYP2C19 extensive metabolizers and poor metabolizers (57). This evidence concerns the gene CYP2C19 and hepatocellular carcinoma.